Lixte appoints Bas van der Baan as independent director; grants 250K options at $0.74

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective June 17, 2022, Bastiaan van der Baan appointed to Board as independent director.
van der Baan brings 20+ years biotech oncology/diagnostics experience to clinical-stage LB-100 development.
Granted options for 250,000 shares at $0.74 (closing price on grant date), 5-year term.
Options vest 50% immediately, then 12.5% quarterly over four quarters, subject to continued service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bastiaan van der Baan

Director

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2022-06-17
Filed: June 23, 2022, 7:59 PM ET

Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bastiaan van der Baan was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.

View on SEC.gov

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-017558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.